For children like Opie, a leukaemia diagnosis can feel like the end of the road. After his first stem cell transplant, Opie was in remission for a few months, but the cancer came back. That’s when he was eligible for CAR T-cell therapy.  Thanks to this cutting-edge therapy, Opie is now four years old and in remission, living proof of the potential for a brighter future.

Currently, CAR T-cell therapy is only available to a small fraction of the addressable patient population who could benefit form these potentially life-saving treatments.  These living medicines have shown incredible clinical success and remain difficult to access in large part due to high costs and complex manufacturing processes.

Oribiotech is on a mission to enable widespread patient access to these therapies through manufacturing technology innovations that deliver on both the scale and reduced manufacturing costs needed to provide cell therapies to patients in need.